Wełnicki Marcin, Mamcarz Artur, Kuchar Ernest, Mitkowski Przemysław, Jaroszewicz Jerzy, Tomasiewicz Krzysztof, Gąsior Mariusz, Leszek Przemysław, Kamiński Karol Adam, Wysocki Jacek
3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 02-091 Warszawa, Poland.
Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, 02-091 Warszawa, Poland.
Vaccines (Basel). 2025 May 23;13(6):554. doi: 10.3390/vaccines13060554.
The COVID-19 pandemic posed a huge challenge to global health systems. In addition to searching for effective methods of treating and preventing infection with a new pathogen, we could once again observe that severe respiratory infection and its complications can be become a challenging problem for cardiac patients. Empirical observations are fully confirmed by the results of clinical trials. Patients with risk factors and already diagnosed with cardiovascular diseases are particularly exposed to the severe course of COVID-19, including death. That is why we consider it so important to promote vaccinations against COVID-19 as a safe and effective method of preventing serious infections in this special group of patients, in accordance with the updated recommendations of relevant experts. If an infection is detected, depending on its form and the risk of hospitalization, there are also several antiviral treatment strategies. Nirmatrelvir/ritonavir therapy is particularly effective in selected patient groups, but its use requires analysis of the cardiac pharmacotherapy regimen in the context of potentially significant drug interactions.
新冠疫情给全球卫生系统带来了巨大挑战。除了寻找治疗和预防新型病原体感染的有效方法外，我们再次观察到，严重呼吸道感染及其并发症可能成为心脏病患者面临的一个具有挑战性的问题。临床试验结果充分证实了经验性观察。有风险因素且已被诊断患有心血管疾病的患者尤其容易出现新冠严重病程，包括死亡。正因为如此，根据相关专家的最新建议，我们认为推广新冠疫苗接种作为预防这一特殊患者群体严重感染的安全有效方法非常重要。如果检测到感染，根据其形式和住院风险，也有几种抗病毒治疗策略。奈玛特韦/利托那韦疗法在特定患者群体中特别有效，但其使用需要在潜在重大药物相互作用的背景下分析心脏药物治疗方案。
